FDA warns Lumimeds over website claims implying its compounded semaglutide and tirzepatide are FDA-approved.
What happened
FDA reviewed the website at https://lumimeds.com in August 2025 and observed that it offers compounded drug products, including semaglutide and tirzepatide. FDA found that website claims suggesting these compounded products were the same as FDA-approved brand-name medicines, including a statement that GLP-1 was FDA-approved for weight loss, were false or misleading because compounded drugs are not FDA-approved.
What FDA found
FDA says the website's claims were false or misleading because they suggested the compounded semaglutide and tirzepatide were the same as FDA-approved brand-name drugs, when compounded drugs are not FDA-approved.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)]FDA says a website statement that GLP-1 was FDA-approved in 2017 and 2021 for weight loss misleads consumers about the approval status of Lumimeds' compounded products.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)]FDA says shipping these misbranded drugs across state lines is a prohibited act.
FDCA section 301(a) [21 U.S.C. § 331(a)]FDA says receiving misbranded drugs in interstate commerce and delivering or offering to deliver them is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells Lumimeds to take immediate action, including ceasing use of the cited language, and to send CDER's Office of Compounding Quality and Compliance a written response within 15 working days describing steps taken and how recurrence will be prevented, with supporting documents.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- online pharmacies and compounding pharmacies marketing semaglutide or tirzepatide
- platforms or brands that host or promote compounded drug claims
This is a summary. Read the original letter on fda.gov.